BioWorld

Jan. 17, 2006

Genelabs' Prestara Headed For New Phase III Lupus Trial

Forging ahead with its lupus drug, Prestara, Genelabs Technologies Inc. has decided to conduct another Phase III trial, and likely will look for a development partner to help offset costs. (BioWorld Today) Read More

Biotech's Redemption Chance: Make Drugs, Foster Community

Human Bird Flu Data: Less Severe, But More Prevalent

FDA Unveils Guidance To Ease Early Stage Clinical Evaluations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...